logoAiPathly

Metsera

M

Overview

Metsera, Inc. is a clinical-stage biopharmaceutical company at the forefront of developing innovative medicines for obesity and metabolic diseases. Key aspects of the company include: Founding and Financing: Established in 2022 by Population Health Partners and ARCH Venture Partners, Metsera has secured $322 million in funding from prominent healthcare investors, including F-Prime Capital, GV, Mubadala Capital, Newpath Partners, and SoftBank Vision Fund 2. Mission and Portfolio: The company aims to accelerate innovation in weight loss treatments and obesity-related conditions. Metsera's portfolio includes oral and injectable incretin, non-incretin, and combination therapies, backed by a proprietary library of over 20,000 gut hormone peptides and peptide/antibody conjugates. Key Development Programs:

  1. MET-097: A long-acting GLP-1 receptor agonist in Phase 1 trials, showing significant weight reduction and potential for monthly dosing.
  2. Dual Amylin/Calcitonin Receptor Agonist (DACRA): Engineered for extended duration of effect.
  3. Unimolecular GGG (GLP-1, GIP, Glucagon): Designed for long-lasting effect and combination with DACRA.
  4. Oral Peptide Delivery Platform: Includes IND-ready candidates and first-in-class oral follow-ons. Clinical Trials: MET-097 has shown promising results in Phase I and Phase IIa trials, demonstrating significant weight loss with good tolerability. Market Position: Metsera is competing with established players like Novo Nordisk and Eli Lilly, offering potential advantages in dosing frequency and tolerability. Leadership: The company is led by industry veterans, including former executives from The Medicines Company, and boasts a strong scientific team headed by Sir Stephen R. Bloom.

Leadership Team

Metsera's leadership comprises experienced professionals in the biopharmaceutical industry: Executive Team:

  • CEO: As of recent updates, a new CEO has taken over from founding CEO Clive Meanwell, M.D.
  • Clive Meanwell, M.D.: Former CEO and British oncologist with a notable industry track record.
  • Whit Bernard: Co-Founder and Chief Operating Officer.
  • Stephen R. Bloom: Senior Vice President of Research and Development, head of drug development at Imperial College London. Key Leaders:
  • Brian Hubbard, Ph.D.
  • John Amatruda, M.D.
  • Christopher Cox
  • Steven Marso, M.D.: Principal author of several papers on semaglutide. Additional Executives:
  • Sheela Kolluri: Senior Vice President and Global Head of Biometrics
  • Virendar Kaushik: Vice President and Project Leader
  • Gbola Amusa: Executive Vice President, Strategic Finance
  • Jason Mallory: Vice President, Clinical Development This diverse team of experts drives Metsera's innovative approaches in obesity and metabolic disease treatments, leveraging their extensive experience in the pharmaceutical industry.

History

Metsera's journey in the biopharmaceutical industry, though recent, has been marked by rapid growth and significant developments: Founding and Funding (2022):

  • Founded by Population Health Partners and ARCH Venture Partners
  • Raised $290 million from leading healthcare investors Leadership and Team:
  • Initially led by CEO Clive Meanwell, a veteran pharmaceutical executive
  • Assembled a team of experienced pharma executives and scientists Portfolio Development:
  • Purpose-built to innovate in obesity and weight loss treatment
  • Developed a broad portfolio of oral and injectable therapies
  • Key programs include GLP-1 receptor agonist, DACRA, and unimolecular GGG agonist Strategic Acquisitions and Partnerships:
  • Acquired U.K.-based biotech Zihipp, gaining access to a vast library of gut hormone peptides
  • Formed a licensing pact with D&D Pharmatech for oral drug technology Clinical Progress:
  • Launched publicly in April 2024
  • Conducted successful Phase 1 trial for MET-097, showing significant weight reduction Future Plans:
  • Advancing MET-097 to Phase IIb trials in Q4 2024
  • Aiming to address comprehensive weight loss therapeutic needs Metsera's rapid progress and innovative approach position it as a significant player in the evolving field of obesity and metabolic disease treatments.

Products & Solutions

Metsera, Inc., a clinical-stage biopharmaceutical company, is at the forefront of developing innovative medicines for obesity and metabolic diseases. Their product pipeline includes:

GLP-1 Receptor Agonists

  • MET-097i: Metsera's lead candidate, a fully-biased, once-monthly, ultra-long acting, subcutaneously injectable GLP-1 receptor agonist. In Phase 2a trials, it demonstrated substantial weight loss, with up to 11.3% mean body weight reduction over 12 weeks. MET-097i utilizes Metsera's proprietary HALO™ peptide lipidation platform, enabling a 15-16 day half-life to support monthly dosing.

Dual Amylin/Calcitonin Receptor Agonist (DACRA)

  • A novel DACRA engineered for class-leading duration of effect, designed to be combined with GLP-1 receptor agonists for enhanced therapeutic efficacy.

Unimolecular GGG Analog

  • A unimolecular analog combining GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon, engineered for extended duration and potential combination with DACRA.

Oral Peptide Delivery Platform

  • Includes two IND-ready candidates with potential best-in-class bioavailability, addressing the challenges of oral peptide delivery.

Combination Therapies

  • Various combinations under development, including MET-097i with ultra-long acting amylin analogue MET-233i and other nutrient-stimulated hormone (NuSH) analog peptide injectables.

HALO™ Peptide Lipidation Platform

  • Proprietary technology enabling peptides to bind simultaneously to albumin and drug targets, resulting in extended half-life, titration-free dosing, and improved tolerability. Metsera's comprehensive portfolio aims to offer scalable, sustainable, and personalized interventions for weight loss, weight maintenance, and metabolic disease prevention, addressing the global obesity crisis through innovative therapeutic strategies.

Core Technology

Metsera's innovative approach to developing treatments for obesity and metabolic diseases is built on several key technological pillars:

Proprietary Peptide Library

  • Access to over 20,000 gut hormone peptides and peptide/antibody conjugates, allowing for versatile combinations in drug development.

GLP-1 Receptor Agonists (GLP-1RAs)

  • Focus on advanced GLP-1RAs, with lead asset MET-097i showing promising results in Phase IIa trials, including significant weight reduction and potential for monthly dosing.

Combination Therapies

  • Development of multi-target treatments, such as dual amylin/calcitonin receptor agonists (DACRA) and unimolecular GGG (GLP-1, GIP, glucagon) analogs, designed to enhance efficacy while minimizing side effects.

Oral Peptide Delivery Platform

  • Innovative platform for oral administration of typically injectable peptides, improving patient experience and compliance.

Long-Acting Injectables

  • Advancement of monthly injectable candidates like MET-097i and MET-233i, aiming to reduce dosing frequency and improve patient outcomes.

Personalized and Sustainable Interventions

  • Strategies for effective weight loss, maintenance, and metabolic disease management, focusing on muscle preservation and improved tolerability.

HALO™ Peptide Lipidation Technology

  • Proprietary platform enabling extended half-life of peptides, supporting less frequent dosing and improved efficacy. Metsera's core technology combines these elements to create a versatile and innovative approach to weight loss and metabolic disease treatments, leveraging a broad portfolio of peptides, combination therapies, and advanced delivery systems.

Industry Peers

Metsera, a clinical-stage biopharmaceutical company focused on obesity and metabolic diseases, competes in a market with several established players:

Novo Nordisk

  • Market leader known for successful GLP-1 receptor agonists Wegovy and Ozempic
  • Sets high standards in weight-loss drug efficacy and market penetration

Eli Lilly

  • Major competitor with highly effective weight-loss drugs Mounjaro and Zepbound
  • Mounjaro, in particular, serves as a benchmark for new market entrants

Viking Therapeutics

  • Emerging player in the obesity drug market
  • Recently reported promising Phase I data for oral obesity candidate VK2735 Metsera's Competitive Strategy:
  1. Broad portfolio development: Oral and injectable drugs targeting multiple pathways
  2. Focus on GLP-1 receptor agonists and combination therapies
  3. Addressing limitations of current treatments:
    • Reducing muscle mass loss
    • Minimizing side effects
    • Potentially surpassing efficacy of existing market leaders
  4. Leveraging proprietary technologies like HALO™ for extended drug half-life
  5. Developing personalized and sustainable interventions for long-term weight management By focusing on innovation and addressing unmet needs in the market, Metsera aims to carve out a significant position in the competitive landscape of obesity and metabolic disease treatments.

More Companies

A

Amplitech Group

AmpliTech Group, Inc. is a leading company specializing in the design, development, and manufacture of advanced radio frequency (RF) and microwave components. The company serves diverse markets, including Commercial, Satellite Communications (SATCOM), Space, and Military sectors, with applications in emerging technologies such as 5G/6G networks, Quantum Computing, and AR/VR. AmpliTech's product range includes low-noise amplifiers (LNAs), power amplifiers, bandpass filters, and other microwave components. These products are renowned for their high performance, ultra-reliability, and efficiency across various frequency bands (50 kHz to 40 GHz, with plans to extend to 100 GHz). Notable offerings include 5G ORAN 64T64R Massive MIMO Radios, low-noise Ka Band LNBs for satellite ground stations, and cryogenic amplifiers for quantum computing applications. The company is recognized for its technological leadership, particularly in developing low-noise cryogenic High Electron Mobility Transistor (HEMT) amplifiers, crucial for quantum computing systems. AmpliTech has received Notices of Allowance from the United States Patent and Trademark Office (USPTO) for its innovations, solidifying its industry position. AmpliTech Group comprises several divisions: AmpliTech Inc., Specialty Microwave, Spectrum Semiconductors Materials, AmpliTech Group Microwave Design Center, and AmpliTech Group True G Speed Services. This structure enables the company to offer a comprehensive range of services and products. Headquartered in Hauppauge, New York, and listed on NASDAQ (AMPG, AMPGW), AmpliTech is committed to developing next-generation communication systems. The company focuses on advancing connectivity across various environments, from space and satellites to homes and smart devices, supporting advancements in AI, quantum science, and other cutting-edge technologies. AmpliTech's mission emphasizes innovation, efficiency, and reliability, positioning the company at the forefront of the RF and microwave component industry.

B

Bitget

Bitget, founded in July 2018 and based in Seychelles, is a comprehensive cryptocurrency exchange and derivatives platform offering a wide range of services and features: ### Services and Trading Options - **Spot Trading**: Users can buy and sell over 800 listed tokens at current market prices. - **Futures Trading**: Offers COIN-M, USDT-M, and USDC-M futures with up to 125x leverage on over 200 margin trading pairs. - **Copy Trading**: Allows users to follow elite traders and benefit from their expertise, supported by Bitget Insights. ### Key Features - **Bitget Insights**: Combines social media with social trading, providing valuable insights from experienced traders. - **Risk Management Tools**: Includes position tiers, futures calculator, and funding rate management. - **Bitget Launchpad**: Offers early access to new cryptocurrency tokens from various projects. ### Security and Transparency - **Dual-Wallet System**: Utilizes cold and hot wallets for optimized security. - **Decentralized Data Warehouse**: First centralized exchange to use this technology, enhancing transparency. ### Global Expansion and Partnerships - Registered in Seychelles to facilitate global expansion. - Partnerships with Lionel Messi, Juventus, and institutional collaborations like Copper. - Launched BitEXC for the Vietnamese market. ### Community and Education - Partnered with IEEE at Manipal University Jaipur for crypto education. - Expanding workforce to support user demand and business growth. ### Additional Initiatives - Introduced GMCI Meme Index for top memecoins. - Upgraded API for improved tax reporting with Koinly. Bitget continues to innovate and expand, focusing on user-centric services, transparency, and global reach in the cryptocurrency trading space.

D

Databricks

Databricks is a comprehensive, cloud-based platform designed for managing, analyzing, and deriving insights from large datasets. It serves as a unified, open analytics platform for building, deploying, sharing, and maintaining enterprise-grade data, analytics, and AI solutions at scale. Key components of Databricks include: - **Workspace**: A centralized, user-friendly web interface for seamless collaboration among data scientists, engineers, and business analysts. - **Notebooks**: Optimized Jupyter notebooks supporting multiple programming languages without context-switching. - **Apache Spark**: The engine for parallel processing of large datasets. - **Delta Lake**: An enhancement over traditional data lakes, providing ACID transactions for data reliability and consistency. Key features and benefits: - **Scalability and Flexibility**: Handles large amounts of data and supports various workloads. - **Integrated Tools and Services**: Includes tools for data preparation, real-time analysis, and machine learning. - **Security and Compliance**: Offers encryption, role-based access control, and auditing features. Use cases for Databricks include: - Data Warehousing - ETL and Data Engineering - Data Analysis and Visualization - Machine Learning and AI Databricks operates on a high-level architecture consisting of a control plane and a compute plane. It is particularly known for its implementation of the lakehouse architecture, which combines the strengths of data warehouses and data lakes. Overall, Databricks streamlines data management, analysis, and AI tasks, making it a valuable tool for organizations seeking to derive insights from their data and build data-driven applications.

K

Kyverna Therapeutics

Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for autoimmune diseases. The company's primary goal is to harness the power of T cells to achieve potentially treatment-free remission by resetting the immune system. ## Lead Product Candidate KYV-101, Kyverna's lead CAR T-cell therapy candidate, targets CD19 and is advancing through clinical trials for various autoimmune diseases: - Phase 2 trials for multiple sclerosis, myasthenia gravis, and stiff-person syndrome - Phase 1/2 trials for systemic sclerosis and lupus nephritis - Ongoing multi-center, open-label Phase 1/2 trials in the US and Germany for lupus nephritis ## Clinical Progress As of July 31, 2024, Kyverna had treated 36 autoimmune patients with KYV-101, reporting promising initial safety and efficacy data. No severe ICANS (Immune Cell-Associated Neurotoxicity Syndrome) or CRS (Cytokine Release Syndrome) Grade ≥3 were reported. KYV-101 has received FDA Regenerative Medicine Advanced Therapy (RMAT) Designations for stiff-person syndrome and myasthenia gravis. ## Pipeline Kyverna is developing next-generation CAR T-cell therapies in both autologous and allogeneic formats, including KYV-201, an allogeneic CD19 CAR T-cell product candidate. ## Leadership Recent key appointments include: - Dan Maziasz as Chief Business Officer - Cara Bauer as Chief Human Resources Officer - Tracy Rossin as Senior Vice President of Corporate Affairs, Communications, and Investor Relations ## Financials Kyverna raised approximately $366.9 million in gross proceeds from its initial public offering in February 2024, supporting the advancement of its clinical development programs. ## Headquarters and Culture Based in the San Francisco East Bay, Kyverna fosters a collegial, collaborative environment that nurtures diverse scientific talent to develop transformative cell therapies. Kyverna Therapeutics stands at the forefront of developing innovative cell therapies aimed at providing durable, immunosuppressant-free remission for patients with severe autoimmune diseases.